Merger

Serina Therapeutics poaches a top chemist to expand its POZ platform, signaling a major push beyond Parkinson's into new, high-value drug markets.

KBRA rates a $328M mortgage trust with significant 'non-prime' loans, signaling a boom in a market segment that balances risk with investor demand.

A rejected $307M Danone offer and claims of poor governance fuel a bitter proxy fight at Lifeway Foods, pitting CEO against her largest shareholder—her brother.

Beyond logistics, new AI-powered systems are redefining trust and efficiency in drug development. See how one company is setting a new human-centered standard.

A regulatory filing uncovers a major bank's intricate derivatives strategy in a £2.3bn takeover, raising questions about market transparency.

A UK regulatory filing reveals a hedge fund's bet against Qualcomm, questioning its major takeover and highlighting the surprising global reach of financial oversight.

Hedge fund Balyasny reveals a 1.26% economic stake in Just Group via derivatives, shining a light on the complex strategies at play in its takeover.

A new report finds 41% of firms have hired fraudulent candidates, exposing a critical gap between AI threats and outdated corporate defenses.

In the heart of oil country, a new boom is taking shape. New Era Energy & Digital is building a gigawatt-scale AI campus, but can it win the infrastructure race?

A Delaware Supreme Court ruling revives a massive liability risk for Loews, extending a seven-year legal battle over its 2018 Boardwalk Pipelines deal.

Rezolute's stock plummets after its lead drug fails a key trial, raising questions about its future and highlighting the brutal realities of biotech.

A rival bid reshaped a major gold merger, creating a West African powerhouse. Here’s how the deal was saved and what it means for the market.

The return of a pharma-finance veteran to MediPharm's board isn't just a personnel change; it's a strategic move to secure its global pharmaceutical ambitions.

Shareholders approve Emeren's $102M deal to go private, a maneuver to accelerate growth in the booming solar and battery storage markets. What's next?

Darling Ingredients' new venture with Tessenderlo isn't just a merger; it's a strategic move to dominate the booming collagen and nutrition market.

A $3 billion drop in assets at AllianceBernstein, driven by client withdrawals in a flat market, signals a deeper challenge for active asset managers.

The lab outfitter's Nu Aire acquisition fuels record revenue, but integration costs and market volatility paint a complex picture of strategic investment.

With a 2026 launch looming, Nuvalent adds a proven oncology dealmaker to its board, signaling a strategic pivot from R&D to market assault.

The 2025 proxy season saw record director support as investors prioritized financials, yet dissent over executive pay signals a new battleground.

Hexagon Purus erases a $12.9M debt in its Panasonic battery deal but gives up lucrative US tax credits, a move securing its supply chain at a high cost.